2.17

0.46% -0.01

After Hours: 2.17

Erasca Inc (ERAS)

Overview News Price History Option Chain Financials Why ERAS Down? Discussions Forecast

Erasca Inc stock is currently priced at $2.17, with a 24-hour trading volume of 668.93K. It has seen a -0.46% decreased in the last 24 hours and a +16.67% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.21 pivot point. If it approaches the $2.14 support level, significant changes may occur.

Previous Close:

$2.18

Open:

$2.16

24h Volume:

668.93K

Market Cap:

$592.02M

Revenue:

Net Income/Loss:

$-125.04M

P/E Ratio:

-1.2191

EPS:

-1.78

Net Cash Flow:

$-122.99M

1W Performance:

-8.63%

1M Performance:

+16.67%

6M Performance:

+11.28%

1Y Performance:

-19.93%

1D Range:

$2.15

$2.24

52W Range:

$1.51

$3.015

Erasca Inc Stock (ERAS) Company Profile

Name

Erasca Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

858-465-6511

Address

10835 Road to the Cure, Suite 140, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ERAS's Discussions on Twitter

Erasca Inc Stock (ERAS) Latest News

A closer look at Erasca Inc (ERAS) is warranted – US Post News - US Post News

US Post News

Taking a look at what insiders are doing to gauge the Erasca Inc (ERAS)'s direction – Knox Daily - Knox Daily

Knox Daily

Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace

BioSpace

Erasca Inc Stock (ERAS) Financials Data

Erasca Inc (ERAS) Net Income 2024

ERAS net income (TTM) was -$125.04 million for the quarter ending December 31, 2023, a +48.50% increase year-over-year.

Erasca Inc (ERAS) Cash Flow 2024

ERAS recorded a free cash flow (TTM) of -$122.99 million for the quarter ending December 31, 2023, a -2.65% decrease year-over-year.

Erasca Inc (ERAS) Earnings per Share 2024

ERAS earnings per share (TTM) was -$0.82 for the quarter ending December 31, 2023, a +58.16% growth year-over-year.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.